Eli Lilly’s acquisition of Loxo Oncology will result in quick return of investment
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
Drug pricing and reimbursement concerns will remain the leading impediment to industry growth in 2019
R&D returns fall to lowest level in 9 years, says Deloitte and GlobalData
Drug development in neuroimmunology to witness strong growth in the 8MM
Immuno-oncology drug development and personalised medicine will continue to reshape the pharma industry in 2019
Bayer receives European approval for haemophilia drug Jivi ... but has stiff competition ahead
GSK and Pfizer deal shows shift in strategy shift to create the leader in over-the-counter products
Big Data and AI to transform healthcare by driving innovation, growing revenues and increasing operational efficiencies
Commercial opportunities for emerging infectious diseases vaccine developers
Second failure of AstraZeneca’s Imfinzi + tremelimumab combination significant setback says GlobalData
Global atopic dermatitis market set to reach $18.3 billion by 2027
Pfizer’s palbociclib is the top breast cancer drug used in clinical trials initiated in 2018
Pharma companies may miss crucial EU drug packaging deadline with a no-deal Brexit
Global chronic lymphocytic leukemia market set to reach $9.2bn by 2027
